Accelerated response and reduced chemotherapy with ruxolitinib-based regimen therapy in pediatric hemophagocytic lymphohistiocytosis: a retrospective comparison with HLH-94 regimen.

Front Immunol · 2026 · PMC13061731 · PMID 41972157

Europe PMC DOI

hedged sentence

0.0760

closest p · 1.5× alpha

0.0760

boldest claim

The sentences

did not reach statistical significanceP = 0.076so close (0.05 < p ≤ 0.1)

A higher CR rate was also noted in patients with markedly elevated baseline alanine aminotransferase (ALT), although this difference did not reach statistical significance (P = 0.076) ( Supplementary Table S2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.